Oxford Biomedica PLC Person Closely Associated Dealing
27 Juin 2024 - 2:57PM
RNS Regulatory News
RNS Number : 2002U
Oxford Biomedica PLC
27 June 2024
Person Closely Associated
Dealing
Oxford, UK - 27 June
2024: Oxford Biomedica plc (LSE:OXB) ("Oxford Biomedica" or "the
Company"), a quality and innovation-led cell and
gene therapy CDMO, today announces that Pippa Radcliffe, a person closely associated with Kyriacos
Mitrophanous, Chief Innovation Officer of the Company, exercised
839 options at nil cost and disposed 274 shares at £3 per share on
25 June 2024.
The below notification, made in
accordance with the requirements of the EU Market Abuse Regulation,
give further details of the transaction.
|
1.
|
Details of the
Person Closely Associated ("PCA")
|
|
a)
|
Name
|
Pippa
Radcliffe
|
|
2.
|
Reason for the
notification
|
|
a)
|
Position/status
|
This notification concerns Pippa
Radcliffe in her capacity as a person closely
associated with a person discharging managerial responsibilities.
The person discharging managerial responsibilities is
Kyriacos Mitrophanous, Chief Innovation Officer
of the Company. The
association arises by virtue of Pippa Radcliffe being the spouse
of Kyriacos
Mitrophanous.
|
|
b)
|
Initial notification/
amendment
|
Initial Notification/Amendment
|
|
3.
|
Details of the
Issuer
|
|
a)
|
Name
|
Oxford Biomedica plc
|
|
b)
|
LEI code
|
213800S1GVQNXQ15K851
|
|
4.
|
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument
Identification code
|
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43
|
|
b)
|
Nature of the transaction
|
Exercise of Options at
nil cost
|
|
c)
|
Currency
|
GBP - British pound
|
|
d)
|
Price(s) and volumes(s)
|
|
Price(s)
|
Volume(s)
|
|
Nil
|
839
|
|
|
e)
|
Aggregated information
-
Aggregate volume
-
Price
-
Aggregated total
|
839
NIL
NIL
|
|
f)
|
Date of the transaction
|
2024-06-25
|
|
g)
|
Place of the transaction
|
London Stock Exchange, Main Market
(XLON)
|
|
1.
|
Details of the
Person Discharging Managerial Responsibility ("PDMR")/person
closely associated with them ("PCA")
|
|
a)
|
Name
|
Pippa
Radcliffe
|
|
2.
|
Reason for the
notification
|
|
a)
|
Position/status
|
This notification concerns Pippa
Radcliffe in her capacity as a person closely
associated with a person discharging managerial responsibilities.
The person discharging managerial responsibilities is
Kyriacos Mitrophanous, Chief Innovation Officer
of the Company. The
association arises by virtue of Pippa Radcliffe being the spouse
of Kyriacos
Mitrophanous.
|
|
b)
|
Initial notification/
amendment
|
Initial Notification
|
|
3.
|
Details of the
Issuer
|
|
a)
|
Name
|
Oxford BioMedica plc
|
|
b)
|
LEI code
|
213800S1GVQNXQ15K851
|
|
4.
|
Details of the
transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument
Identification code
|
Ordinary Shares of 50 pence each
ISIN: GB00BDFBVT43
|
|
b)
|
Nature of the transaction
|
Disposal
|
|
c)
|
Currency
|
GBP - British pound
|
|
d)
|
Price(s) and volumes(s)
|
|
Price(s)
|
Volume(s)
|
|
£3
|
274
|
|
|
e)
|
Aggregated information
-
Aggregate volume
-
Price
-
Aggregated total
|
274
£3
£822.00
|
|
f)
|
Date of the transaction
|
2024-06-25
|
|
g)
|
Place of the transaction
|
London Stock Exchange, Main Market
(XLON)
|
-Ends-
|
For further
information, please contact:
|
|
|
Oxford
Biomedica plc:
Natalie Walter, Company Secretary
|
Tel: +44 (0)1865 783 000
|
ABOUT OXFORD
BIOMEDICA
Oxford Biomedica (LSE: OXB) is a quality and
innovation-led contract development and manufacturing organisation
(CDMO) in cell and gene therapy with a mission to enable its
clients to deliver life changing therapies to patients around the
world.
One of the original pioneers in cell and gene
therapy, OXB has more than 25 years of experience in viral vectors;
the driving force behind the majority of cell and gene therapies.
OXB collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector
development and manufacturing expertise in lentivirus,
adeno-associated virus (AAV), adenovirus, and other viral vector
types. Oxford Biomedica's world-class capabilities span from
early-stage development to commercialisation. These capabilities
are supported by robust quality-assurance systems, analytical
methods and depth of regulatory expertise.
Oxford Biomedica, a FTSE4Good constituent, is
headquartered in Oxford, UK. It has
bioprocessing and manufacturing facilities across Oxfordshire, UK,
Lyon and Strasbourg, France, and near Boston, MA, US. Learn more
at www.oxb.com, and follow us on
LinkedIn
and YouTube.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
DSHFLFEFRVIDFIS
Oxford Biomedica (LSE:OXB)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
Oxford Biomedica (LSE:OXB)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024
